Clinical trials: Hypercholesterolemia, completed
Hyperlipidemia
A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. A study to look at lipid levels in subjects taking the study drug, Atorvastatin alone or placebo.
- Trial name
- NCT00138762
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 154 sites in United States, Belgium and 6 more
- Volunteers
- 3,800 people
- Sponsor
- Pfizer
Cardiovascular Diseases, Heart Diseases
Evaluation of Childhood Blood Pressure and Lipid Screening
To help clarify the validity, reliability, and utility of blood pressure (BP) and lipid screening in childhood.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Hypercholesterolemia, Hypertension
- Trial name
- NCT00005439
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cardiovascular Diseases, Heart Diseases
Genetics of Low Density Lipoprotein Subclasses in Hypercholesterolemia
To perform genetic studies of low density lipoprotein (LDL) subclasses in 160 families in whom the probands had metabolically defined hypercholesterolemia.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Hypercholesterolemia
- Trial name
- NCT00005203
- Sponsor
- University of Washington
Coronary Arteriosclerosis, Hypercholesterolemia
Comparative Atorvastatin Pleiotropic Effects
The primary objective of the study is to evaluate the efficacy of atorvastatin 80 mg daily as compared to atorvastatin 10 mg daily in reducing C-reactive protein levels over a 26-week treatment period in subjects with documented…
- Trial name
- CAP (NCT00163202)
- Testing
- Blood samples, Atorvastatin
- Where
- 74 sites in Canada, Czechia and 5 more
- Volunteers
- 330 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetes Mellitus, Dyslipidemia
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
Background- Statins are a safe and effective therapy to reduce cardiovascular risk in patients with type 2 diabetes; however some patients are not prescribed statins, others do not take it even after being prescribed, and others…
- Conditions
- Diabetes Mellitus, Dyslipidemia, Hypercholesterolemia, Cardiovascular Disease
- Trial name
- NCT00217061
- Testing
- Decision Aid Statin Choice
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Mayo Clinic
Hypercholesterolemia
Study on the Effect of the Intake of a Calcium-bicarbonate Water on Cholesterol Levels
The goal of this study is to evaluate the hypolipidemic effect (reduction of Low Density Lipoprotein Cholesterol "LDL-C" values) of calcium-bicarbonate mineral water "Lete" (alkaline water, high in bicarbonate and calcium ions…
- Trial name
- NCT07026266
- Testing
- Water
- Where
- Italy
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Società Generale delle Acque Minerali S.p.A.
Dyslipidemias, High Cholesterol
Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
This study will be a placebo-controlled, double-blind, randomized, phase 3 study to Evaluate the Efficacy, Safety, and Tolerability of Obicetrapib in Participants with a History of Heterozygous Familial Hypercholesterolemia…
- Conditions
- Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia
- Trial name
- BROOKLYN (NCT05425745)
- Testing
- Obicetrapib
- Where
- 96 sites in United States, Canada and 8 more
- Volunteers
- 354 people
- Sponsor
- NewAmsterdam Pharma
Hypercholesterolemia, Familial
Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study
The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with placebo, on percent change from baseline in LDL-C in adults with heterozygous familial…
- Trial name
- RUTHERFORD (NCT01375751)
- Testing
- Evolocumab
- Volunteers
- 168 people
- Sponsor
- Amgen
Heterozygous Familial Hypercholesterolemia, Elevated Cholesterol
Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)
This is a Phase III, placebo-controlled, double-blind, randomized study in participants with HeFH and elevated LDL-C to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) injection(s) of inclisiran.
- Trial name
- ORION-9 (NCT03397121)
- Testing
- Inclisiran
- Where
- 45 sites in United States, Canada and 6 more
- Volunteers
- 482 people
- Sponsor
- The Medicines Company
Diabetes Mellitus Type 2, Dyslipidemia
Omentectomy for the Treatment of Diabetes Mellitus Type 2
The purpose of this study is to determine whether laparoscopic removal of the omentum (thin layer of fat inside the abdomen) will significantly improve insulin resistance in patients with non-insulin dependent type 2 diabetes…
- Conditions
- Diabetes Mellitus Type 2, Dyslipidemia, Hypercholesterolemia, Obesity
- Trial name
- NCT00270439
- Testing
- removal of omentum
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Vanderbilt University
Dyslipidemia, Hypercholesterolemia
A Study to Evaluate Fasting/Postprandial Serum Apolipoprotein B-48 (ApoB-48) Levels in Diabetic Participants With Normal to Moderately High Low Density Lipoprotein-C (LDL-C) Levels (MK-0653A-259 AM1)
This study will evaluate whether fasting/postprandial serum ApoB-48 levels are increased in diabetic participants compared to nondiabetic participants with the same range of serum LDL-C levels, and whether ApoB-48 levels can be…
- Trial name
- NCT01333436
- Testing
- Test Meal
- Where
- South Korea
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
The primary objective of the study was to assess the long-term safety and tolerability of alirocumab in patients with heFH who were receiving concomitant treatment with hydroxymethyl glutaryl-coenzyme A (HMG-CoA) reductase…
- Trial name
- NCT01576484
- Testing
- Alirocumab
- Where
- 14 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Regeneron Pharmaceuticals
Hypercholesterolemia
Effect of High Stanol Ester Dose on Serum Lipids, Carotenoids and Fat-soluble Vitamins
The aim was to investigate the effects of the consumption of high doses of plant stanol esters on concentrations of serum lipids, carotenoids and fat soluble vitamins.
- Trial name
- maxsta (NCT00698256)
- Testing
- vegetable oil-based spread and oat-based drink (no brand name available)
- Where
- Finland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Marjukka Kolehmainen
Hypercholesterolemia
Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
The primary objectives of this study are to evaluate the safety of MD-0727 in patients with primary hypercholesterolemia and to determine the low density lipoprotein cholesterol (LDL-C) lowering effect and dose-response of…
- Trial name
- NCT00404001
- Testing
- MD-0727
- Where
- 20 sites in United States
- Volunteers
- 150 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Cardiovascular Diseases, Heart Diseases
Dietary Treatment of Hyperlipidemia in Women vs. Men
To conduct a dietary intervention trial to test the lipid lowering response to the National Cholesterol Education Program (NCEP) Step Two Diet by free-living hyperlipidemic women and men and to compare the response between them.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Hypercholesterolemia
- Trial name
- NCT00005336
- Sponsor
- University of Washington
Hypercholesterolemia
A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks.
The primary objective is to determine the effect of WelChol tablets on serum lipids, lipoproteins, apolipoproteins, and lipoprotein particle size in patients who were stabilized on simvastatin therapy for at least 4 weeks.
- Trial name
- NCT00753779
- Testing
- colesevelam HCl tablets, and simvastatin tablets
- Where
- 14 sites in United States
- Volunteers
- 72 people
- Sponsor
- Daiichi Sankyo
Hypercholesterolemia, Dyslipidemia
Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin
The primary objective of this study is to evaluate the pharmacokinetics and pharmacodynamics of a single dose of PF-04950615 (RN316) in volunteers on stable doses of atorvastatin.
- Trial name
- NCT01163851
- Testing
- 4 mg/kg, 0.5 mg/kg
- Where
- 5 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypercholesterolemia
A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)
This study will evaluate the efficacy and safety and tolerability of 2 dose levels of MK-0653H in Japanese participants. The primary hypotheses are that the administration of MK-0653H is safe and tolerable and that MK-0653H is…
- Trial name
- NCT02741245
- Testing
- Ezetimibe 10 mg, Rosuvastatin 2.5 mg
- Volunteers
- 321 people
- Sponsor
- Organon and Co
Hypercholesterolemia
How Cricket Powder Affects Gut Microbiome and Cholesterol Metabolism
Cardiovascular disease (CVD) is the leading cause of death worldwide, including in Thailand. One of the major risk factors for CVD is dyslipidemia, or abnormal levels of cholesterol and other fats in the blood.
- Trial name
- CricketOnME (NCT07009756)
- Testing
- Cricket Powder
- Where
- Thailand
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Hypercholesterolemia
Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment
To evaluate the efficacy of subcutaneous (SC) evolocumab, compared to regularly scheduled low-density lipoprotein cholesterol (LDL-C) apheresis, on reducing the need for future apheresis.
- Trial name
- NCT02585895
- Testing
- Evolocumab, Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
- Where
- 17 sites in United States, Australia and 6 more
- Volunteers
- 39 people
- Sponsor
- Amgen